USP Announces Corrections to General Chapter <1132.1> on Residual Host Cell Protein Measurement
Recommendation

3/4 February 2026
Evaluation, Implementation and Use of Suitable Technologies
The United States Pharmacopeia (USP) has announced minor corrections to General Chapter <1132.1> Residual Host Cell Protein Measurement in Biopharmaceuticals by Mass Spectrometry. The chapter was originally published in Pharmacopeial Forum 49(3) and subsequently approved for publication on 01 November 2024, in USP-NF 2025, Issue 1.
The following errata were published on 31 January 2025, and all changes will take effect on 01 May 2025:
- Section 1. INTRODUCTION AND SCOPE – In paragraph 3: Change Residual HCP ELISA to: HCP ELISA.
- Section 4. SAMPLE PREPARATION, CHROMATOGRAPHIC SEPARATION, AND MASS SPECTROMETRY ANALYSIS – In paragraph 4 in 4.1 Sample Preparation: Change product (or polysorbate) to: product protein (or polysorbate).
- Section 5. QUANTITATION OF HCPS – In three instances in 5.1 Methods for HCP Quantitation: Change product to: product protein.
- Section 7. BEST PRACTICES FOR REPORTING DATA FROM ELISA VERSUS LC-MS/MS – In paragraph 1 in 7.3 Comparison of ELISA and LC-MS/MS HCP Results: Change the comparing to: comparing.
For a comprehensive list of errata, refer to the USP-NF Errata Table.
Additionally, please see the Notice of Intent to Revise, published on 01 November 2024, for further details.
Related GMP News
18.12.2025FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books
18.12.2025Questions and Answers on System Suitability Tests (SST) - Part 1
18.12.2025PharmaLab 2025: Brief Summary of AQCG Track - Save the Date for 2026!
18.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
17.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
17.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity


